Manufacturer of the investigational cholesterol modifying agent anacetrapib (Merck) has released surprising early data from the drug’s cardiovascular outcomes study REVEAL that could potentially reinvigorate waning interest in HDL targeted therapies. In a press release Merck said the late stage trial involving nearly 30,000 patients had met its primary endpoint, significantly reducing major coronary events ...
HDL-hypothesis reinvigorated with early data from REVEAL
By Sunalie Silva
3 Jul 2017